STOCK TITAN

Pieris Pharmaceuticals Inc - PIRS STOCK NEWS

Welcome to our dedicated news page for Pieris Pharmaceuticals (Ticker: PIRS), a resource for investors and traders seeking the latest updates and insights on Pieris Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pieris Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pieris Pharmaceuticals's position in the market.

Rhea-AI Summary
Pieris Pharmaceuticals announced a 1-for-80 reverse stock split to comply with Nasdaq's minimum bid price requirement, reducing outstanding shares to 1.2 million from 98.9 million, effective April 23, 2024. The split aims to maintain listing on the Nasdaq Capital Market under the symbol PIRS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Pieris Pharmaceuticals (PIRS) announced a strategic update to maximize potential milestones from its immuno-oncology assets partnered with Pfizer, Boston Pharmaceuticals, and Servier. The company aims to extend its cash runway into 2027 through cost-saving measures. Despite unsuccessful negotiations for a strategic merger, Pieris plans to focus on stockholder value by maintaining a lean business model and pursuing milestone and royalty monetization agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
none
-
Rhea-AI Summary
Pieris Pharmaceuticals achieves milestone payment from Boston Pharmaceuticals for dosing first patient in phase 1/2 study of BOS-342, a biotherapeutic for respiratory diseases and cancer. Pieris could receive up to $350 million in milestone payments and royalties on sales of BOS-342.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.88%
Tags
Rhea-AI Summary
Pieris Pharmaceuticals provides a strategic update following recent events that impacted its respiratory franchise. AstraZeneca discontinues enrollment in Phase 2a study for elarekibep and terminates R&D collaboration agreement. Pieris focuses on new partnerships, capital preservation, and cost-saving measures. The company retains Stifel, Nicolaus & Company as its exclusive financial advisor for strategic options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
none
-
Rhea-AI Summary
Pieris Pharmaceuticals announced that AstraZeneca has decided to discontinue and cease dosing in the clinical studies of elarekibep, an inhaled asthma treatment. This decision was based on lung findings from a non-clinical toxicology study. Pieris will review the implications of the data and AstraZeneca's decision before providing an update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-70.84%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.98%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
Pieris Pharmaceuticals Inc

Nasdaq:PIRS

PIRS Rankings

PIRS Stock Data

16.99M
61.19M
7.44%
39.36%
0.14%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Boston

About PIRS

pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche